No Data
No Data
Perspective Therapeutics Initiated at Overweight by Cantor Fitzgerald
Perspective Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Perspective Therapeutics With Overweight Rating
Cantor Fitzgerald analyst Louis Chen initiates coverage on Perspective Therapeutics with a Overweight rating.
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced
FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors
FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors
Perspective Therapeutics Price Target Raised to $1.70/Share From $1.20 by B. Riley Securities
Perspective Therapeutics Price Target Raised to $1.70/Share From $1.20 by B. Riley Securities
No Data